Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Predictors of the response to adalimumab in rheumatoid arthritis.

Trial Profile

Predictors of the response to adalimumab in rheumatoid arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Feb 2009 Planned number of patients changed to 200 as reported by ClinicalTrials.gov.
    • 04 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top